Value-Based Cardiology


The approval of evolocumab (Repatha) creates competition in the new class of PCSK9 cholesterol-fighting therapies and managed care plans and pharmacy benefit managers are expected to take full advantage to hold down costs.
In addition to risk for liver damage, people with hepatitis C may also have an increased risk of heart disease, according to a new Johns Hopkins study published in The Journal of Infectious Diseases.
The move comes after Sanofi and Regeneron spent $67.5 million to move ahead of the main competitor in the FDA approval process.
The Sanofi and Regeneron therapy, to be marketed as Praluent, was among the most-anticipated FDA approvals of the year. Late-day reports put pricing at $40 a day wholesale, well above estimates, although insurers will seek discounts.
Instead of making patients suffering from life-limiting illnesses choose between hospice care and curative care, CMS will test coverage that allows individuals to receive palliative and curative treatment concurrently.


July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI